Physician profile

Fonda A Evins

Family · North Little Rock, AR

NPI 1144727108

$155.62

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genentech USA, INC. $27.03 2021-2022
Lundbeck LLC $24.34 2021
Pfizer INC. $24.01 2024
Sunovion Pharmaceuticals INC. $23.41 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $16.23 2021
Janssen Pharmaceuticals, INC $14.35 2021
Boehringer Ingelheim Pharmaceuticals, INC. $13.18 2021
Lilly USA, LLC $13.07 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Fonda A Evins

$155.62

in general payments reported 2019-2025

Years
2021-2024
Top company
Genentech USA, INC.

https://glasscript.com/doctor/10690826/fonda-a-evins

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.